Total Payments
$76,246
2024 Payments
$28,989
Companies
43
Transactions
240
Medicare Patients
6,582
Medicare Billing
$1.3M
Payment Breakdown by Category
Other$56,238 (73.8%)
Food & Beverage$7,177 (9.4%)
Consulting$6,616 (8.7%)
Travel$6,215 (8.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $56,238 | 18 | 73.8% |
| Food and Beverage | $7,177 | 201 | 9.4% |
| Consulting Fee | $6,616 | 5 | 8.7% |
| Travel and Lodging | $6,215 | 16 | 8.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $37,444 | 28 | $0 (2024) |
| GENZYME CORPORATION | $13,071 | 9 | $0 (2024) |
| Madrigal Pharmaceuticals | $9,637 | 10 | $0 (2024) |
| Phathom Pharmaceuticals, Inc. | $4,796 | 8 | $0 (2024) |
| PFIZER INC. | $2,798 | 18 | $0 (2023) |
| ABBVIE INC. | $1,601 | 54 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,500 | 1 | $0 (2023) |
| Adare Pharmaceuticals, Inc. | $1,244 | 5 | $0 (2020) |
| Regeneron Pharmaceuticals, Inc. | $668.00 | 2 | $0 (2024) |
| Gilead Sciences, Inc. | $609.64 | 38 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,989 | 53 | Takeda Pharmaceuticals U.S.A., Inc. ($13,180) |
| 2023 | $16,645 | 32 | GENZYME CORPORATION ($12,002) |
| 2022 | $1,972 | 29 | GENZYME CORPORATION ($1,048) |
| 2021 | $588.72 | 17 | AbbVie Inc. ($192.50) |
| 2020 | $4,672 | 9 | Takeda Pharmaceuticals U.S.A., Inc. ($3,393) |
| 2019 | $15,262 | 17 | Takeda Pharmaceuticals U.S.A., Inc. ($14,731) |
| 2018 | $7,099 | 31 | Takeda Pharmaceuticals U.S.A., Inc. ($6,123) |
| 2017 | $1,019 | 52 | UCB, Inc. ($244.32) |
All Payment Transactions
240 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 12/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $3.43 | General |
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/05/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $326.40 | General |
| Category: LIVER DISEASE | ||||||
| 11/19/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $3.11 | General |
| 11/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.05 | General |
| 11/11/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $25.17 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: Iron Deficiency Anemia | ||||||
| 10/28/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,740.50 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/24/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $117.80 | General |
| Category: INFLAM | ||||||
| 10/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.95 | General |
| 10/08/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,176.50 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,935.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $281.94 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $254.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $226.86 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $186.86 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $94.62 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $80.91 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $77.39 | General |
| Category: LIVER DISEASE | ||||||
| 09/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,958.50 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/17/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $27.45 | General |
| Category: IMMUNOLOGY | ||||||
| 09/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Travel and Lodging | In-kind items and services | $941.42 | General |
| Category: INTERNAL MEDICINE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 1,741 | 42,716 | $1.9M | $555,552 |
| 2022 | 25 | 1,810 | 19,172 | $1.8M | $470,418 |
| 2021 | 18 | 1,566 | 1,874 | $891,102 | $153,313 |
| 2020 | 21 | 1,465 | 18,294 | $905,090 | $151,123 |
Total Patients
6,582
Total Services
82,056
Medicare Billing
$1.3M
Procedure Codes
89
All Medicare Procedures & Services
89 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 19 | 21,000 | $840,000 | $365,204 | 43.5% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 154 | 156 | $148,200 | $30,673 | 20.7% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 107 | 107 | $69,683 | $18,326 | 26.3% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 13 | 19,500 | $58,500 | $17,191 | 29.4% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 303 | 528 | $165,938 | $12,844 | 7.7% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Office | 2023 | 146 | 193 | $77,675 | $12,005 | 15.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 153 | 161 | $121,287 | $11,413 | 9.4% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Office | 2023 | 149 | 215 | $49,963 | $10,879 | 21.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 108 | 120 | $31,610 | $10,148 | 32.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 82 | 84 | $82,334 | $9,427 | 11.4% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 69 | 71 | $56,387 | $9,411 | 16.7% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 107 | 109 | $70,850 | $7,223 | 10.2% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 43 | 43 | $27,449 | $7,178 | 26.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 36 | 41 | $15,163 | $5,073 | 33.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 39 | 110 | $18,891 | $4,975 | 26.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 31 | 31 | $12,916 | $4,264 | 33.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 55 | 55 | $12,715 | $3,873 | 30.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 12 | 44 | $11,552 | $3,749 | 32.5% |
| 46946 | Tying of multiple internal hemorrhoid groups | Facility | 2023 | 11 | 11 | $7,949 | $3,266 | 41.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $8,927 | $2,938 | 32.9% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 16 | 16 | $31,853 | $1,472 | 4.6% |
| 76981 | Ultrasound scan of organ tissue for measuring elasticity | Office | 2023 | 19 | 19 | $3,753 | $1,394 | 37.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 20 | $3,710 | $1,094 | 29.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 12 | 45 | $3,039 | $855.67 | 28.2% |
| 91065 | Measurement of hydrogen in breath to test for stomach and bowel symptoms | Office | 2023 | 11 | 11 | $1,843 | $677.60 | 36.8% |
About Dr. Mousab Tabbaa, MD
Dr. Mousab Tabbaa, MD is a Gastroenterology healthcare provider based in Westlake, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1184642050.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mousab Tabbaa, MD has received a total of $76,246 in payments from pharmaceutical and medical device companies, with $28,989 received in 2024. These payments were reported across 240 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($56,238).
As a Medicare-enrolled provider, Tabbaa has provided services to 6,582 Medicare beneficiaries, totaling 82,056 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 89 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Westlake, OH
- Active Since 07/18/2006
- Last Updated 01/19/2024
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1184642050
Products in Payments
- Entyvio (Biological) $20,510
- ENTYVIO (Biological) $16,924
- REZDIFFRA (Drug) $9,637
- VOQUEZNA (Drug) $4,796
- DUPIXENT (Biological) $2,821
- VELSIPITY (Drug) $2,400
- XIFAXAN (Drug) $1,533
- LIBTAYO (Biological) $668.00
- RINVOQ (Biological) $528.20
- Mavyret (Drug) $524.05
- STELARA (Biological) $506.45
- XELJANZ (Drug) $346.65
- Cimzia (Drug) $244.32
- GI GENIUS (Device) $184.08
- SKYRIZI (Biological) $170.78
- Bylvay (Drug) $146.81
- DIFICID (Drug) $134.09
- SPYGLASS (Device) $124.28
- OCALIVA (Drug) $124.01
- REMICADE (Biological) $122.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Westlake
Mohamed Naem, Md, MD
Gastroenterology — Payments: $502,724
Gastroenterology $502,724
Preeti Jhawar, Do, DO
Gastroenterology — Payments: $32,669
Gastroenterology $32,669
Rinjal Brahmbhatt, Md, MD
Gastroenterology — Payments: $24,119
Gastroenterology $24,119
Peter Greenwalt, Md, MD
Gastroenterology — Payments: $10,592
Gastroenterology $10,592
Dr. Iqbal Ahmed, Md, MD
Gastroenterology — Payments: $9,547
Gastroenterology $9,547
Jonathan Umbel, D.o, D.O
Gastroenterology — Payments: $6,028
Gastroenterology $6,028